Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
25 10 2022
25 10 2022
Historique:
received:
05
11
2021
accepted:
13
06
2022
pubmed:
18
8
2022
medline:
27
10
2022
entrez:
17
8
2022
Statut:
ppublish
Résumé
To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy. This was a retrospective cohort study from 2 large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12 months were included in the analysis. The primary study outcome was annualized relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation. A total of 14,213 patients, with 18,029 eligible treatment discontinuation epochs, were identified for 7 therapies. Annualized rates of relapse (ARRs) started to increase 2 months after natalizumab cessation (month 2-4 ARR 0.47, 95% CI 0.43-0.51). Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation (mean ARR difference: 0.15, 0.08-0.22). After discontinuation of fingolimod, rates of relapse increased overall (month 1-2 ARR: 0.80, 0.70-0.89) and stabilized faster in patients who started a new therapy within 1-2 months (mean ARR difference: 0.14, -0.01 to 0.29). The magnitude of disease reactivation for other therapies was low but reduced further by commencement of another treatment 1-10 months after treatment discontinuation. Predictors of relapse were a higher relapse rate in the year before cessation, female sex, younger age, and higher EDSS score. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, 95% CI 0.72-0.81) and disability accumulation (0.73, 0.65-0.80). The rate of disease reactivation after treatment cessation differs among MS treatments, with the peaks of relapse activity ranging from 1 to 10 months in untreated cohorts that discontinued different therapies. These results suggest that untreated intervals should be minimized after stopping antitrafficking therapies (natalizumab and fingolimod). This study provides Class III that disease reactivation occurs within months of discontinuation of MS disease-modifying therapies. The risk of disease activity is reduced by commencement of a subsequent therapy.
Sections du résumé
BACKGROUND AND OBJECTIVES
To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy.
METHODS
This was a retrospective cohort study from 2 large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12 months were included in the analysis. The primary study outcome was annualized relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation.
RESULTS
A total of 14,213 patients, with 18,029 eligible treatment discontinuation epochs, were identified for 7 therapies. Annualized rates of relapse (ARRs) started to increase 2 months after natalizumab cessation (month 2-4 ARR 0.47, 95% CI 0.43-0.51). Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation (mean ARR difference: 0.15, 0.08-0.22). After discontinuation of fingolimod, rates of relapse increased overall (month 1-2 ARR: 0.80, 0.70-0.89) and stabilized faster in patients who started a new therapy within 1-2 months (mean ARR difference: 0.14, -0.01 to 0.29). The magnitude of disease reactivation for other therapies was low but reduced further by commencement of another treatment 1-10 months after treatment discontinuation. Predictors of relapse were a higher relapse rate in the year before cessation, female sex, younger age, and higher EDSS score. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, 95% CI 0.72-0.81) and disability accumulation (0.73, 0.65-0.80).
DISCUSSION
The rate of disease reactivation after treatment cessation differs among MS treatments, with the peaks of relapse activity ranging from 1 to 10 months in untreated cohorts that discontinued different therapies. These results suggest that untreated intervals should be minimized after stopping antitrafficking therapies (natalizumab and fingolimod).
CLASSIFICATION OF EVIDENCE
This study provides Class III that disease reactivation occurs within months of discontinuation of MS disease-modifying therapies. The risk of disease activity is reduced by commencement of a subsequent therapy.
Identifiants
pubmed: 35977837
pii: WNL.0000000000201029
doi: 10.1212/WNL.0000000000201029
pmc: PMC9620810
doi:
Substances chimiques
Natalizumab
0
Fingolimod Hydrochloride
G926EC510T
Immunosuppressive Agents
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1926-e1944Informations de copyright
© 2022 American Academy of Neurology.
Références
Mult Scler. 2017 Apr;23(5):647-655
pubmed: 27481209
Neurology. 2017 Oct 10;89(15):1584-1593
pubmed: 28916537
JAMA Neurol. 2016 Jul 1;73(7):790-4
pubmed: 27135594
N Engl J Med. 2000 Nov 16;343(20):1430-8
pubmed: 11078767
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neurology. 2011 May 31;76(22):1858-65
pubmed: 21543733
Ann N Y Acad Sci. 1965 Mar 31;122:552-68
pubmed: 14313512
J Neurol. 2014 Jun;261(6):1170-7
pubmed: 24728334
J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1133-7
pubmed: 27298148
Neurology. 2014 Apr 8;82(14):1204-11
pubmed: 24610329
J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):52-6
pubmed: 17846110
Mult Scler. 2016 Apr;22(4):520-32
pubmed: 26199347
Mult Scler. 2014 Apr;20(4):471-80
pubmed: 23950550
Brain. 2006 Mar;129(Pt 3):606-16
pubmed: 16415308
Mult Scler. 2016 Nov;22(13):1642-1648
pubmed: 27270498
Neurology. 2014 Apr 29;82(17):1491-8
pubmed: 24682966
Ann Neurol. 2005 Dec;58(6):840-6
pubmed: 16283615
Mult Scler Relat Disord. 2017 Jul;15:A1-A2
pubmed: 28641776
Mult Scler Relat Disord. 2017 Oct;17:123-127
pubmed: 29055441
Eur J Neurol. 2018 Oct;25(10):1270-1275
pubmed: 29851435
Neurol Neuroimmunol Neuroinflamm. 2016 Oct 28;3(6):e297
pubmed: 27844037
Mult Scler. 2015 Nov;21(13):1713-22
pubmed: 25698174
Am J Epidemiol. 2008 Sep 15;168(6):656-64
pubmed: 18682488
JAMA Neurol. 2020 Sep 1;77(9):1132-1140
pubmed: 32511687
Brain. 2015 Nov;138(Pt 11):3287-98
pubmed: 26359291
Neurol Neuroimmunol Neuroinflamm. 2020 Aug 14;7(6):
pubmed: 32801166
Am J Epidemiol. 2010 Mar 15;171(6):691-700
pubmed: 20139124
J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647
pubmed: 28572277
Neurol Ther. 2019 Dec;8(2):241-250
pubmed: 31677060
Lancet. 2002 Dec 21-28;360(9350):2018-25
pubmed: 12504397
Mult Scler J Exp Transl Clin. 2015 Jan-Dec;1:
pubmed: 26550483
J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468
pubmed: 30636699
Mult Scler. 2006 Dec;12(6):769-74
pubmed: 17263005
J Neurol Sci. 2018 Aug 15;391:72-76
pubmed: 30103975
Ann Neurol. 2016 Jul;80(1):89-100
pubmed: 27145331
Mult Scler. 2017 Aug;23(9):1241-1248
pubmed: 27765877
Mult Scler Relat Disord. 2018 Oct;25:95-98
pubmed: 30056362
Brain. 2006 Mar;129(Pt 3):595-605
pubmed: 16415309
Mult Scler Relat Disord. 2020 Feb;38:101868
pubmed: 31877445
Mult Scler. 2019 Dec;25(14):1828-1834
pubmed: 31120376
Mult Scler. 2020 Jan;26(1):118-122
pubmed: 30541380
Mult Scler. 2012 Feb;18(2):143-52
pubmed: 22312009
Ther Adv Neurol Disord. 2019 Mar 29;12:1756286419837809
pubmed: 30956686